132nok
-3,8 %
Date:2025-06-06Time:09:41:18Latest report:Q4-2023List:Oslo BorsTicker:BGBIO
Market Cap:53 mnokEnterprise Value:-87 mnokNet Sales:0,85 mnokEarnings:-139,3 mnokEmployees:0ISIN:NO0013251173

Ratios

10-year key figure history for BerGenBio turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for BerGenBio with index and moving average MA50 and MA200.

Stockprice:1,32
MA50:1,74
MA200:6,61
Price/MA200:-79,6 %
RSI (14):30,0
Price/MA50:-22,3 %

Description

BerGenBio is a Norwegian oncology company. The company conducts research and development of inhibitory drugs for the treatment of aggressive cancers. The company has developed a number of products whose composition intends to block the protein AXL, a protein positively related to the spread of cancer cells. The company was founded in 2007 and is headquartered in Bergen.

Biotechnology